Omada Health is trading at $19.08, up 5.65%, with healthcare’s 2.12% gain supporting a sector-wide explanation for the move. - No company-specific announcement on October 20 was found that clearly explains the gain. - An October 19 report described Omada’s planned PREDICTS diabetes-prevention trial with Wake Forest and UNMC, but did not link it to the share-price movement. - The company’s next reported catalyst is Q3 results scheduled for November 5.